drugset / Trial / NCT04580654
A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults
Non-randomizedSequentialOpen-labelOther
Summary
This will be a 2- part, phase 1, open-label, single center, single ascending dose study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of subcutaneous (SC) and intravenous (IV) administration of CSL312 in healthy adult Japanese and Caucasian subjects.
Timeline
- Start
- 2020-10-29
- Primary completion
- 2021-05-07
- Completion
- 2021-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CSL312 | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.